Figure 4 - full size

Figure 4.
The experimental electron densities of EGFR and c-Src-cys at 2.95 Å and 2.48 Å resolution, respectively, are shown (2F[o] – F[c] map contoured at 1 ). (a) Optimized EGFR inhibitor 2 (PD 168393)^13 (green ball and sticks) in complex with the EGFR kinase domain shows clear electron density between the targeted Cys797 and the acrylamide Michael acceptor on 2. The inhibitor makes a direct hydrogen bond between its quinazoline N1 and the main chain amide of Met793, which is a common recognition motif among reversible anilinoquinazolines and several protein kinase domains^16, ^20, ^21, ^22, ^23, ^24. We find the cocrystal complex in an active conformation of EGFR: a conserved salt bridge found only in active EGFR conformations between the catalytic Lys745 and helix C Glu762 remains intact. The m-bromine group sits adjacent (within 3.4 Å) to the gatekeeper residue, Thr790. (b) Notably, structures of 2 in complex with c-Src-cys show an inhibitor binding mode distinct from any reported for anilinoquinazolines with a protein kinase. In molecule B of the c-Src-cys–2 complex, 2 (green ball and sticks) forms a water-mediated (W1) hydrogen bond via its N1 of the quinazoline core to the backbone amide of Met341.